New drug applications approved by US FDA as of 01-15 December 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Treatment with lotilaner ophthalmic solution 0.25% twice daily for 6 weeks is well tolerated by patients with Demodex blepharitis and has no serious adverse effects compared to a vehicle control, according to a study. Moreover, use of this drop results in clinically meaningful outcomes.
Use of calcium-channel blockers (CCBs) appears to increase the risk of developing glaucoma, suggests a study. In addition, use of systemic beta blockers is associated with lower intraocular pressure (IOP).
Myopia prevalence in school-age children has reached record high in Hong Kong and may remain high over the next few years, a cross-sectional study by researchers from the Chinese University of Hong Kong (CUHK) has found.
Retinal thinning predicts disability in patients newly diagnosed with relapsing multiple sclerosis (MS), an immune-mediated disease affecting the brain and spinal cord, in a new study presented at EAN 2023.
Treatment with dexamethasone implant results in better outcomes for patients with persistent or recurrent uveitic macular edema (ME) at 12 weeks when compared with methotrexate or ranibizumab, a study has shown. The risk of intraocular pressure (IOP), however, is higher with dexamethasone, but elevations to levels of 30 mm Hg or more are rare.
New drug applications approved by US FDA as of 16-31 August 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.